The HCPLive uveitis page is a comprehensive resource for clinical news and insights on chorioretinitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for eye inflammation, and more.
January 21st 2024
Patients with uveitis switched from adalimumab originator to SB5 did not experience clinically significant differences in treatment efficacy and safety.
Vision Impairment Associated with Developing Mental Health Conditions
November 17th 2023After years 1, 3, and 5, patients with diabetic retinopathy patients had increased odds of depression and suicide, patients with glaucoma had increased odds for all mental health conditions with higher odds for suicide or suicide ideation, and patients with AMD had increased odds for depression.
Adalimumab Biosimilar for Uveitis Similarly Efficacious to Bio-Originator
March 22nd 2023Data from the United Kingdom indicate Amgevita is safe and effective for non-infectious uveitis with non-inferiority to originator adalimumab, but a significant number of patients requested to switch back due to adverse events.